恶性胸膜间皮瘤:DNA修复基因胚系变异可能指导个体化治疗
该研究对113例未经选择的恶性胸膜间皮瘤患者进行107个癌症易感基因的胚系DNA二代测序,约7%(8/113)的患者检出致病性变异,多数位于DNA修复相关基因。体外实验显示,ATM缺陷的间皮瘤球体经他泽司他处理后出现凋亡诱导,提示DNA修复缺陷患者可能从诱导合成致死的治疗中获益。
要点
- 113例未经选择的恶性胸膜间皮瘤患者中,约7%(8/113)检出致病性变异。
- 多数致病性变异位于参与或推测参与DNA修复的基因,包括BRCA1、BRIP1、CHEK2、SLX4、FLCN和BAP1。
- ATM缺陷的间皮瘤球体经他泽司他处理后出现凋亡诱导,提示DNA修复不足患者可能获益。
核心结论
- 总体数据提示,DNA修复功能不足的恶性胸膜间皮瘤患者可能从该治疗中获益,该治疗诱导合成致死。
研究设计与样本
- 对113例未经选择的恶性胸膜间皮瘤患者进行胚系DNA二代测序,使用包含107个癌症易感基因的定制面板。
- 建立三维间皮瘤细胞模型,该模型存在共济失调毛细血管扩张突变(ATM)缺陷,ATM是DNA修复的主要调控因子,用于研究DNA修复不足条件下对选定药物的反应。
主要发现
- 在约7%的恶性胸膜间皮瘤患者(8/113)中鉴定出致病性变异。
- 在另一例家族性恶性胸膜间皮瘤患者中鉴定出BAP1的新致病性变异。
- 多数致病性变异位于参与或推测参与DNA修复的基因(BRCA1、BRIP1、CHEK2、SLX4、FLCN和BAP1)。
- 体外研究显示,ATM沉默或抑制的间皮瘤球体经zeste同源物2增强子抑制剂他泽司他处理后出现凋亡诱导。
临床怎么用
- 作者认为,DNA修复功能不足的恶性胸膜间皮瘤患者可能从诱导合成致死的治疗中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a tumour associated with asbestos exposure. Approximately, 10% of patients with MPM carry a germline pathogenic variant (PV), mostly in DNA repair genes, suggesting the occurrence of inherited predispositions. AIM: This article aimed to 1) search for new predisposing genes and assess the prevalence of PVs in DNA repair genes, by next-generation sequencing (NGS) analysis of germline DNA from 113 unselected patients with MPM and 2) evaluate whether these patients could be sensitive to tailored treatments. METHODS: NGS was performed using a custom panel of 107 cancer-predisposing genes. To investigate the response to selected drugs in conditions of DNA repair insufficiency, we created a three-dimensional-MPM cell model that had a defect in ataxia telangiectasia mutated (ATM), the master regulator of DNA repair. RESULTS: We identified PVs in approximately 7% of patients with MPM (8/113) and a new PV in BAP1 in a further patient with familial MPM. Most of these PVs were in genes involved or supposedly involved in DNA repair (BRCA1, BRIP1, CHEK2, SLX4, FLCN and BAP1). In vitro studies showed apoptosis induction in ATM-silenced/inhibited MPM spheroids treated with an enhancer of zeste homologue 2 inhibitor (tazemetostat). CONCLUSIONS: Overall these data suggest that patients with MPM and DNA repair insufficiency may benefit from this treatment, which induces synthetic lethality.
引用
- Sculco M, La Vecchia M, Aspesi A, et al. Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. Eur J Cancer. 2022. PMID: 35032816. doi:10.1016/j.ejca.2021.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。